Year None 2024 2023 2022 2021 2020 2019 2018 2017 Phase 2 study of the first-in-class oral innate immune activation BXCL701 with pembrolizumab in patients with Metastic Castration-Resistant Prostate Cancer (MCRPC): ESMO 2024 Poster September 13, 2024
Phase 2 study of the first-in-class oral innate immune activation BXCL701 with pembrolizumab in patients with Metastic Castration-Resistant Prostate Cancer (MCRPC): ESMO 2024 Poster September 13, 2024
